Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
NCT ID: NCT01402401
Last Updated: 2020-12-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
21 participants
INTERVENTIONAL
2011-11-30
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AUY922 + Trastuzumab
AUY922
Trastuzumab
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AUY922
Trastuzumab
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Written informed consent obtained prior to any screening procedures
2. Patients with documented cytological or histological confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma and proven HER2 positive.
3. Patients with progressive disease (radiological confirmation required according to RECIST) after first line of trastuzumab in combination with chemotherapy for advanced gastric cancer.
4. Age ≥ 18 years or age of consent in country of residence and able to sign Informed Consent
5. ECOG performance status of 0-1 at study entry
6. HER2-overexpressing positive gastric tumor by IHC3+ or IHC2+ with positive in situ hybridization
7. Measurable disease according to RECIST (Irradiated lesions can not be considered measurable unless they have clearly progressed since radiotherapy).
8. Negative serum pregnancy test. The serum pregnancy test must be obtained prior to any drug administration (≤ 72 hours prior to dosing) in all pre-menopausal women and for women \< 2 years after the onset of menopause.
9. Patients must have the following laboratory values:
Hematologic
* Absolute Neutrophil Count (ANC) ≥1.5x109/L,
* Hemoglobin (Hgb) ≥ 9 g/dL,
* Platelets (plt) ≥100x109/L
Biochemistry:
* Serum total bilirubin ≤ 1.5 x ULN
* Serum albumin \> 2.5 g/dl
* Serum creatinine ≤ 1.5 x ULN or 24-hour clearance ≥ 50 ml/min.
* AST/SGOT and ALT/SGPT ≤ 2.5 x Upper Limit of Normal (ULN) or ≤ 5.0 x ULN if liver metastases are present
Exclusion Criteria
1. Evidence of spinal cord compression or current evidence of CNS metastases. CT/MRI of the brain is mandatory (within 3 weeks before study start) in case of clinical suspicion or evidence of brain metastases
2. Patient who are \< 4 weeks since last chemotherapy or treatment with another systemic anti-cancer agent. Patients must have recovered (CTC ≤ 1) from acute toxicities of any previous therapy (with the exception of alopecia).
3. Patients may have received prior radiotherapy for management of local disease providing that disease progression has been documented, all toxicities have resolved (CTC ≤ 1) (with the exception of alopecia), and the last fraction of radiotherapy was completed at least 4 weeks prior to the study.
4. Prior treatment with an agent that acts via HER2/c-erbB2 targeting other than 1st line trastuzumab, include (but are not limited to) lapatinib and pertuzumab.
5. Treatment with therapeutic doses of coumarin-type anticoagulants. (Maximum daily dose of 2 mg, for line patency permitted)
6. Patients with malignant ascites that require invasive treatment
7. Patients with acute or chronic renal disease; and active and chronic liver disease requiring intervention. Other concurrent severe and/or uncontrolled medical conditions that could cause unacceptable safety risks or compromise compliance with the protocol.
8. Major surgery ≤ 2 weeks prior to enrollment or who have not recovered from such therapy
9. Impaired cardiac function
10. Concurrent malignancies or invasive cancers diagnosed within the past 5 years, except for adequately treated basal cell cancer of the skin or in situ cancer of the cervix
11. Patients receiving chronic or high dose corticosteroids therapy (Inhaled steroids and short courses of oral steroids for anti-emesis or as an appetite stimulant are allowed)
12. Patients unwilling or unable to comply with the protocol
13. Patients known to be HIV positive. Testing is not required in the absence of clinical signs and symptoms suggesting HIV infection.
14. Known hypersensitivity to any of the study drugs or their excipients
15. Participation in another clinical study within 30 days before first study treatment
16. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\> 5 mIU/mL).
17. Fertile women of childbearing potential (WOCBP) not using adequate contraception (abstinence, oral contraceptives, intrauterine device or barrier method of contraception in conjunction with spermicidal jelly or surgically sterile).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California at Los Angeles UCLA LeConte Location
Los Angeles, California, United States
Clinical Research Alliance
Lake Success, New York, United States
University of Texas/MD Anderson Cancer Center UT SC
Houston, Texas, United States
Novartis Investigative Site
Leuven, , Belgium
Novartis Investigative Site
Bordeaux, , France
Novartis Investigative Site
Nice, , France
Novartis Investigative Site
Reims, , France
Novartis Investigative Site
Mannheim, Baden-Wurttemberg, Germany
Novartis Investigative Site
Heilbronn, , Germany
Novartis Investigative Site
Modena, MO, Italy
Novartis Investigative Site
Kashiwa, Chiba, Japan
Novartis Investigative Site
Sapporo, Hokkaido, Japan
Novartis Investigative Site
Seoul, Korea, South Korea
Novartis Investigative Site
Seoul, Korea, South Korea
Novartis Investigative Site
Barcelona, Catalonia, Spain
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Results for CAUY922A2205 can be found on the Novartis Clinical Trial Results website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-002570-23
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CAUY922A2205
Identifier Type: -
Identifier Source: org_study_id